论文部分内容阅读
目的探讨缓解期哮喘患者血小板活化状态及糖皮质激素的影响。方法采用流式细胞仪单抗检测方法，观察正常人及缓解期哮喘患者吸入二丙酸倍氯米松治疗６个月前后血小板膜糖蛋白（ＧＰ）的变化及与ＦＥＶ１变化的关系。结果缓解期哮喘患者治疗前ＧＰⅠｂ、ＧＰⅠｂ／ⅠＸ、ＧＰⅡｂ／Ⅲａ和ＧＭＰ－１４０较正常人升高（均为Ｐ＜００５）。吸入二丙酸倍氯米松治疗后，哮喘ＧＰⅠｂ、ＧＰⅡｂ／Ⅲａ、ＧＭＰ－１４０比治疗前降低（Ｐ＜００５），而且ＧＰⅡｂ／Ⅲａ、ＧＭＰ－１４０的变化均与ＦＥＶ１的变化呈正相关关系。结论缓解期哮喘患者存在血小板活化现象，吸入二丙酸倍氯米松可通过抑制血小板活化而减低气道阻力及气道慢性炎症；ＧＰⅡｂ／Ⅲａ、ＧＭＰ－１４０可作为判定吸入糖皮质激素疗效的指标之一。
Objective To investigate the effects of glucocorticoid on platelet activation and asthma in patients with remission. Methods Flow cytometry monoclonal antibody detection method was used to observe the changes of platelet membrane glycoprotein (GP) and its relationship with the changes of FEV1 after inhalation of beclometasone dipropionate for 6 months in normal subjects and remission asthmatic patients. Results The levels of GPⅠb, GPⅠb / ⅠX, GPⅡb / Ⅲa and GMP-140 in asthmatic patients before remission were higher than those in normal controls (all P <005). After inhaled beclometasone dipropionate treatment, the GPⅠb, GPⅡb / Ⅲa and GMP-140 in asthma were lower than those before treatment (P <005), and the changes of GPⅡb / Ⅲa and GMP-140 were positively correlated with the changes of FEV 1 . Conclusions Platelet activation is observed in asthmatic patients during remission. Inhalation of beclomethasone dipropionate can reduce airway resistance and chronic airway inflammation by inhibiting platelet activation. GPⅡb / Ⅲa and GMP-140 can be used as indicators to determine the efficacy of inhaled corticosteroids one.